TABLE 5.

The use of anti-HER2 ligand in various nano formulations to target HER2 receptors.

Nanocarrier	Therapeutic agent(s)	Conjugates	Clinical outcome	References
HER2 immunoliposomes and liposomes in combination	Bevacizumab in a liposome and doxorubicin in an immunoliposome	Inhibition in HER2/MDR BC patiemts	Reduced the tumour size and lower toxicity	Tang et al. (2021)
Polymalic acid based nano drug	Antisense oligonucleotides	The polymer-attached 12-mer peptide mimicking trastuzumab recognises HER2+ cells	Decrease the tumour size	Ding et al. (2017)
Ethylenediamine functionalized single-walled nanotube	Oncogene suppressor p53	Increased uptake by MCF-7 cells	Leading to enhanced caspase-3-induced apoptosis	Karmakar et al. (2011)
HER2 antibody-coated gold nanoparticles and gold sulphide	Gold–gold sulphide for high- intensity photoablation	Bind with SK-BR-3 cells overexpressing HER2	Promotes thermal damage to tumour	Day et al. (2010)
Trastuzumab-modified gold nanoparticles with 111-In labelling	Radioactive-111-in	Local its injection to mice with sc MDA-MB-361	Tumours arrested	Chinen et al. (2015)